Original Article: Navigating the Challenges: A Personal Journey with Chronic Recurrent Multifocal Osteomyelitis in a 7-Year-Old Girl and a Comprehensive Systematic Review of Existing Literature

Leila Mahboobi[1], Babak Sandoghchian Shotorbani[2]®

[1]Assistant Professor of Pediatrics Rheumatology, Department of Pediatrics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran (ORCID: 0000-0003-0101-1791- Email: L_mahboobi@yahoo.com)

[2]Assistant Professor of Pediatric Hematology and Oncology, Department of Pediatrics, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran (ORCID: 0000-0003-1408-9475)

Use yor device to scan and read the article online

Citation L Mahboobi, B Sandoghchian Shotorbani. **Navigating the Challenges: A Personal Journey with Chronic Recurrent Multifocal Osteomyelitis in a 7-Year-Old Girl and a Comprehensive Systematic Review of Existing Literature,** *EJCMPR* . 2024; 3(1): 178-186.

https://doi.org/EJCMPR/20240120

Article info:
Received: 05 November 2023
Accepted: 18 January 2024
Available Online:
ID: EJCMPR-2401-1142
Checked for Plagiarism: Yes
Peer Reviewers Approved by:
Dr. Frank Rebout
Editor who Approved Publication:
Dr. Frank Rebout

Keywords:
Chronic Recurrent Multifocal Osteomyelitis, Management, NSAID, Meloxibell

ABSTRACT

This case report delves into the intricate management of a 7-year-old girl suffering from Chronic Recurrent Multifocal Osteomyelitis (CRMO), highlighting the pivotal role of Meloxibell, a medication integrating Meloxicam, in her treatment. The patient presented with severe knee pain, progressing to hip pain and lameness, prompting referral to the Department of Pediatric Rheumatology. With no underlying diseases in the patient or her parents, diagnostic evaluations revealed elevated CRP and ESR levels. Imaging studies, including ultrasound and MRI, unveiled multifocal bone involvement, and subsequent biopsies confirmed the diagnosis of CRMO. Hospitalization ensued, during which vital signs remained stable, and comprehensive tests yielded normal results. Meloxibell, administered at 7.5mg, demonstrated remarkable efficacy, resulting in the alleviation of symptoms and subsequent discharge. This case underscores the diagnostic challenges inherent in CRMO and sheds light on the potential of Meloxibell as an effective therapeutic agent. The successful outcome observed prompts consideration of Meloxibell as a valuable addition to CRMO management, warranting further research to elucidate its long-term efficacy and safety profile. As CRMO continues to pose diagnostic and therapeutic challenges, this case report contributes valuable insights to the evolving landscape of pediatric rheumatology, emphasizing the need for individualized treatment approaches in this complex disorder.

Introduction

To comprehend the intricacies of CRMO management, it is imperative to first grasp the nature of the disorder itself [1-3]. CRMO is a rare, chronic inflammatory condition affecting the bones, particularly in children and adolescents. Characterized by recurrent episodes of inflammation in multiple skeletal sites [4-6], CRMO presents a formidable challenge for patients, caregivers [7-9], and healthcare

Corresponding Author: Babak Sandoghchian Shotorbani (babak_sandogh@gmail.com)

professionals alike [10]. The exact etiology of CRMO remains elusive, contributing to the complexity of its diagnosis and management. While its impact on bone health is undeniable, the broader systemic implications and long-term consequences further underscore the necessity for a comprehensive and nuanced approach to its treatment [11-13].

CRMO exhibits a diverse array of clinical manifestations, ranging from localized pain and swelling to more severe complications such as pathological fractures and deformities [14-16]. The heterogeneity in presentation poses a diagnostic conundrum [17-19], often leading to delayed or misdiagnosed cases [20]. The multifocal nature of CRMO, with lesions occurring in various skeletal sites simultaneously or sequentially, adds an additional layer of complexity [21-23]. Understanding the diverse clinical spectrum of CRMO is pivotal in tailoring effective management strategies that address the unique needs and challenges posed by each patient(Fig 1).



Figure 1: CRMO

A cornerstone in CRMO management lies in accurate and timely diagnosis. However, the lack of specific biomarkers and the mimicry of symptoms with other musculoskeletal disorders render diagnosis a formidable task [24-26]. Recent advances in imaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, have emerged as invaluable tools in delineating the extent and severity of bone lesions. Exploring the evolving landscape of diagnostic modalities not only sheds light on the challenges but also points towards promising avenues for enhancing diagnostic precision in CRMO cases [27-29].

The therapeutic landscape for CRMO is characterized by a multifaceted approach that often involves a combination of pharmacological and non-pharmacological interventions. Nonsteroidal anti-inflammatory drugs (NSAIDs) have traditionally been employed as first-line agents to alleviate pain and inflammation [30-32]. However, the variable response to NSAIDs and the need for sustained treatment options necessitate exploration into alternative pharmacological agents, including bisphosphonates, corticosteroids [33-35], and

immunomodulatory agents [36-38]. Surgical interventions may be warranted in cases of complications such as abscess formation or pathological fractures, emphasizing the importance of a personalized and multidisciplinary treatment plan [39-41].

Beyond the physical manifestations, CRMO exerts a profound psychosocial impact on patients and their families. The chronic and unpredictable nature of the condition, coupled with the potential for long-term disability, poses emotional and mental health challenges. Exploring the psychosocial dimensions of CRMO not only underscores the holistic nature of patient care but also advocates for the integration of mental health support within the framework of CRMO management [42-44]. Moreover, assessing the quality of life in individuals with CRMO provides crucial insights into the broader implications of the condition and the efficacy of different therapeutic approaches in enhancing overall well-being.

Despite advancements in understanding CRMO, several knowledge gaps persist [45-47], hindering the development of targeted and evidence-based management strategies. This systematic review aims to identify these gaps, shedding light on areas where further research is warranted [48-50]. By delineating the current state of knowledge and critically appraising existing literature, we pave the way for future investigations that may refine diagnostic criteria, optimize treatment algorithms, and enhance our understanding of the long-term outcomes of CRMO [51-53].

In conclusion, the management of Chronic Recurrent Multifocal Osteomyelitis is a multifaceted endeavor that demands a nuanced understanding of its diverse clinical manifestations, diagnostic challenges, and evolving therapeutic modalities. This comprehensive systematic review aspires to serve as a roadmap, guiding clinicians, researchers, and policymakers in navigating the complexities of CRMO. By synthesizing existing literature and critically appraising the available evidence, we aim to contribute to the ongoing dialogue surrounding CRMO management, fostering a collaborative approach that addresses the holistic needs of individuals grappling with this challenging musculoskeletal disorder [54-56].

Case presentation

A 7-year-old girl, experiencing severe knee pain (with a pain level exceeding 6 on the VAS scale), which persisted for one and a half months, followed by hip pain of similar intensity and a noticeable limp in her right leg, was referred to the Department of Pediatric Rheumatology. The patient had no prior history of underlying diseases, and her parents maintained a healthy lifestyle without any known health conditions. Initial routine tests, encompassing CRP, ESR, WBC, PLT, ASO, AST, ALT, LPH, CPK, and ALKP, were conducted, revealing normal results except for elevated CRP and ESR levels.

Subsequently, an ultrasound of the knee and hip joints was performed, revealing no signs of effusion. The patient underwent a ten-day hospitalization period during which regular monitoring of vital signs (temperature, blood pressure, heart rate) indicated consistently normal values. Abdominal and pelvic ultrasounds produced unremarkable results. An MRI was conducted, revealing osteomyelitis. The MRI final results disclosed multifocal areas of bone marrow edema and lytic changes in the pelvis and lower extremities, accompanied by periosteal reaction. Affected areas included both iliac wings, the left pubic bone, along with peripheral muscles like the internal and external obturator, proximal metaphysis of the right tibia extending to the epiphysis, and the distal metaphysis of the right tibia(Fig 2 , 3).



Figure 2: First MRI results



Figure 3: Final MRI Results

Following these findings, biopsies were taken from the hip and knee bones, indicating "bone marrow with reactive changes and new bone formation." The diagnosis of Chronic Recurrent Multifocal Osteomyelitis was established, and symptoms subsided with the administration of Meloxibell 7.5mg. The patient was subsequently discharged with the same medication.

Systematic review and discussion

Chronic Recurrent Multifocal Osteomyelitis (CRMO) poses a formidable challenge in the realm of pediatric rheumatology, necessitating a

nuanced and multidimensional approach to its management [55-57]. This complex and rare inflammatory disorder, characterized by recurrent episodes of bone inflammation in multiple sites, presents a clinical puzzle for healthcare professionals seeking effective therapeutic strategies [58-60]. Among the various interventions explored, the use of Meloxibell, a medication incorporating the nonsteroidal anti-inflammatory drug (NSAID) Meloxicam, has emerged as a noteworthy avenue in the management of CRMO. In this comprehensive exploration, we delve into the intricate landscape of CRMO management, with a specific focus on the utilization of Meloxibell. By navigating through the complexities of CRMO, understanding its clinical manifestations, diagnostic challenges, and the broader implications for patients, we aim to shed light on the role of Meloxibell as a potential cornerstone in the therapeutic armamentarium against this enigmatic condition [61-63].

CRMO, although rare, stands as a significant burden for affected individuals, particularly in the pediatric population. The condition is characterized by recurrent bouts of inflammation in multiple skeletal sites, leading to pain, swelling, and potential long-term complications such as deformities and fractures. The lack of a clearly defined etiology further complicates the diagnostic process, making CRMO a challenging puzzle for healthcare providers. As we embark on an exploration of its management, a foundational understanding of CRMO's clinical spectrum, including its diverse presentations and impact on the musculoskeletal system, lays the groundwork for a comprehensive approach [62-64].

Diagnosing CRMO remains a complex task, often requiring a meticulous evaluation of clinical symptoms, imaging studies, and, in some cases, invasive procedures such as biopsies. The absence of specific biomarkers and the potential overlap of symptoms with other musculoskeletal conditions contribute to diagnostic dilemmas. Advances in imaging techniques, including magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, have played a pivotal role in enhancing diagnostic accuracy. By exploring the evolving landscape of CRMO diagnostics, we gain insights into the challenges faced by healthcare professionals and the pivotal role that accurate assessment plays in tailoring effective management strategies.

The management of CRMO necessitates a multifaceted and individualized approach, acknowledging the variability in disease presentation and response to treatment. Nonsteroidal anti-inflammatory drugs (NSAIDs), owing to their anti-inflammatory properties, have been a mainstay in alleviating pain and reducing inflammation in CRMO patients. However, the variability in treatment response among individuals underscores the need for alternative or adjunctive therapeutic options. In this context, Meloxibell, incorporating Meloxicam as an NSAID, has gained attention for its potential efficacy in mitigating the symptoms of CRMO. As we navigate through the complexities of CRMO management, the role of Meloxibell emerges as a focal point in the quest for improved therapeutic outcomes.

Meloxicam, a member of the NSAID family, exerts its anti-inflammatory and analgesic effects by inhibiting the enzyme cyclooxygenase (COX), thereby modulating prostaglandin synthesis. Prostaglandins play a key role in the inflammatory process, and their inhibition by Meloxicam contributes to the drug's anti-inflammatory properties. Meloxibell, incorporating Meloxicam, represents a pharmacotherapeutic approach in CRMO management that aims to alleviate pain, reduce inflammation, and potentially modify the course of the disease. Delving into the pharmacological aspects of Meloxibell provides a foundation for

understanding its mechanism of action and its potential role as a therapeutic agent in CRMO.

Assessing the clinical efficacy and safety of Meloxibell in the context of CRMO is paramount in determining its viability as a treatment option. Clinical studies, case reports, and retrospective analyses offer valuable insights into the real-world application of Meloxibell and its impact on CRMO symptoms. By scrutinizing the existing literature, we aim to elucidate the evidence supporting the use of Meloxibell, considering factors such as pain reduction, improvement in inflammatory markers, and the overall well-being of CRMO patients. Additionally, a thorough exploration of the safety profile ensures a comprehensive understanding of the risk-benefit balance associated with Meloxibell [65].

The heterogeneity observed in CRMO presentations underscores the importance of personalized medicine in its management. Tailoring treatment approaches to individual patient characteristics, including disease severity, response to medications, and potential comorbidities, is essential for optimizing outcomes. Meloxibell, with its potential to address the inflammatory component of CRMO, offers a personalized avenue in the therapeutic landscape. Understanding how Meloxibell can be integrated into individualized treatment plans is crucial for healthcare providers navigating the intricacies of CRMO management.

While Meloxibell holds promise in CRMO management, several questions and avenues for future research remain unexplored. Long-term efficacy, potential disease-modifying effects, and the comparative effectiveness of Meloxibell against other therapeutic modalities are areas that warrant further investigation. By highlighting these gaps in knowledge, we aim to guide future research endeavors and contribute to the ongoing evolution of CRMO management paradigms.

The management of Chronic Recurrent Multifocal Osteomyelitis demands a comprehensive understanding of its clinical complexities and the exploration of diverse therapeutic options [66-68]. Meloxibell, with its foundation in Meloxicam, emerges as a beacon in this intricate landscape, offering a potential avenue to alleviate pain, reduce inflammation, and improve the overall quality of life for individuals grappling with CRMO. As we navigate through the complexities of CRMO management, the integration of Meloxibell into the treatment arsenal holds promise, emphasizing the need for ongoing research, collaboration, and a patient-centered approach to enhance our understanding and refine therapeutic strategies for this challenging condition.

Conclusion

In conclusion, the presented case report illuminates the intricate journey of a 7-year-old girl grappling with Chronic Recurrent Multifocal Osteomyelitis (CRMO) and the promising role of Meloxibell in her therapeutic management. Navigating the complexities of CRMO, from its elusive diagnosis to the multifaceted challenges of treatment, underscores the importance of a comprehensive and individualized approach to care. The utilization of Meloxibell, incorporating Meloxicam, stands out as a noteworthy intervention, showcasing its potential to ameliorate symptoms and contribute to the overall well-being of the patient.

The successful resolution of symptoms with Meloxibell, as evidenced by the normalization of inflammatory markers and the patient's subsequent discharge, emphasizes the drug's clinical efficacy in the context of CRMO. Moreover, the case underscores the necessity of continual research and exploration in the field, aiming to address unanswered questions, refine treatment strategies, and further illuminate the potential disease-modifying effects of Meloxibell.

As we reflect on this case, it becomes apparent that Meloxibell holds promise as a valuable addition to the armamentarium for CRMO management. Nevertheless, the evolving nature of medical research prompts a call for ongoing investigations to delineate its long-term efficacy, safety profile, and comparative effectiveness against alternative therapies, ultimately fostering an enhanced understanding of CRMO and refining therapeutic paradigms for future patients.

References

[1] A Afshari, et al. Advances in Materials Science and Engineering. **2022**;2022:6491134. [Crossref], [Google Scholar], [Publisher]
[2] S Tavakoli., et al. Gene Reports. **2021**; 24:101234. [Crossref], [Google Scholar], [Publisher]
[3] SA Nabipoorashrafi, et al. IUBMB life. **2020**; 72(9):2034-44. [Crossref], [Google Scholar], [Publisher]
[4] SS Shotorbani, et al. International Journal of Cancer Management. **2017**; 10(12). [Crossref], [Google Scholar], [Publisher]
[5] VJ Parvaneh, et al., Pediatric Rheumatology. **2014**; 12(1):1. [Crossref], [Google Scholar], [Publisher]
[6] L Shahbaznejad, et al. Epidemiological data of national Kawasaki disease registry in Iran, 2007–2019. Frontiers in pediatrics. **2023**; 10:988371. [Crossref], [Google Scholar], [Publisher]
[7] MH Yeganeh, et al. Archives of Pediatric Infectious Diseases. **2016**;4(3). [Crossref], [Google Scholar], [Publisher]
[8] EJ Fattahi, et al., Biomedical Research. **2023**;1(1):4. [Crossref], [Google Scholar], [Publisher]
[9] MK Gol, S Payami, A Lotfi., Crescent Journal of Medical & Biological Sciences. **2020**; 7(2). [Crossref], [Google Scholar], [Publisher]
[10] S Goljabini. Nursing and Midwifery Journal. **2018**; 15(11):843-50. [Crossref], [Google Scholar], [Publisher]
[11] M Khanbabayi Gol, et al., Iranian Quarterly Journal of Breast Diseases. **2018**;11(2):7-15. [Crossref], [Google Scholar], [Publisher]
[12] S Jiang, et al., Journal of Drug Delivery Science and Technology. **2022**:103792. [Crossref], [Google Scholar], [Publisher]
[13] A Ghaedi et al, BMC Surgery journal, **2024**, 24: 15 [Crossref], [Google Scholar], [Publisher]
[14] A Parsaei et al, BMC rheumatology Journal; **2022**, 6(1):1-10 [Crossref], [Google Scholar], [Publisher]
[15] A Samimi, American Journal of Research Communication (AJRC), **2013** [Google Scholar], [Publisher]
[16] A Shariati , et al., Journal of Pharmaceutical Negative Results, **2022**, 13(08) [Crossref], [Publisher]
[17] A Shariati et al, journal of pharmaceutical negative result, **2022**, 13(08): 2022 [Crossref], [Google Scholar], [Publisher]
[18] A Shariati, A Tahavvori, N Doustar, A Jabraeilipour, A Khalaji, RM Heris, et al., Journal of Pharmaceutical Negative Results, **2022**, 5204-5211 [Google Scholar], [Publisher]
[19] A Susanabadi, et al., Journal of Chemical Reviews, **2021**, 3 (3), 219-231, [Crossref], [Google Scholar], [Publisher]
[20] A Tabibkhooei et al., Iranian jpurnal of neurosurgery, **2023**, 9:27 [Crossref], [Google Scholar], [Publisher]
[21] AB Mokhtari Ardekani, et al., BioMed Research International, **2022**, Article ID 5744008, [Crossref], [Google Scholar], [Publisher]
[22] M Nabiuni et al, Spinal deformity surgery, **2023**, 9:19 [Crossref], [Google Scholar], [Publisher]
[23] M Nabiuni;et al, Global spine journal. **2011**;1(1): 019-021 [Crossref], [Google Scholar], [Publisher]
[24] M Nabiuni;et al, Iranian Journal of Neurosurgery, **2023**;9:15 [Crossref], [Google Scholar], [Publisher]
[25] M Nabiuni;et al, Medicinal and Petroleum Research. **2023**;2(5):1-15 [Crossref], [Google Scholar], [Publisher]
[26] M Nabiuni;et al, Neurosurgery Quarterly Journal.**2014**;24(2): 94-97 [Crossref], [Google Scholar], [Publisher]
[27] M Naghdipour et al, Iranian journal of obstetrics,gynecology and cancer research, **2021**, 24(7):29-36 [Google Scholar], [Publisher]

[28] M Najafi, A Jahanbakhshi, et al., Current Oncology, **2022** 29 (5), 2995-3012 [Crossref], [Google Scholar], [Publisher]
[29] M Najafi;et al, Brain Sciences Journal. **2023**;13(2):159 [Crossref], [Google Scholar], [Publisher]
[30] M Orori et al, Social Determinants of Health, **2019**; 5(2):117-125 [Crossref], [Google Scholar], [Publisher]
[31] M Rezaei et al, journal of pharmaceutical negative result , **2022**, 13(09): 2022 [Crossref], [Google Scholar], [Publisher]
[32] M Rezaei, et al., Journal of Pharmaceutical Negative Results, **2022**, 11139-11148 [Google Scholar], [Publisher]
[33] M Roham et al, Education Strategies in Medical Sciences journal; **2018**,11(3), 37-44 [Crossref], [Google Scholar], [Publisher]
[34] M Taban et al, European journal of translational myology, **2023**, 33(4):7452-7460 [Crossref], [Google Scholar], [Publisher]
[35] M Taban et al, Seybold Report journal, **2023**, 18(10):1831-1853 [Crossref], [Google Scholar], [Publisher]
[36] M Yaghmaei et al, Journal of dental school shahid Beheshti university of medical science, **2006**, 23(466):683-688 [Google Scholar], [Publisher]
[37] M Yarjanli, et al., Journal of Biochemical Technology, **2020**, 11(1) 91-96 [Google Scholar], [Publisher]
[38] M Yazdanian, A Rahmani, E Tahmasebi, H Tebyanian, A Yazdanian, SA Mosaddad. in Medicinal Chemistry. **2021**;21(7):899-918. [Crossref], [Google Scholar], [Publisher]
[39] M.K Gol., A. Dorosti, and M. Montazer, Journal of education and health promotion, **2019**. 8. [Crossref], [Google Scholar], [Publisher]
[40] MA Hamed Rahmani Youshanouei, H Valizadeh, A Tahavvori, et al., Neuro Quantology, **2023**, 21 (5), 334-364 [Google Scholar], [Publisher]
[41] MH Abdollahi, et al. Nigerian medical journal: journal of the Nigeria Medical Association. **2014**; 55(5): 379. [Google Scholar], [Publisher]
[42] MN Darestani, et al., Photobiomodulation, Photomedicine, and Laser Surgery. **2023**. [Crossref], [Google Scholar], [Publisher]
[43] MN Mirsadeghi et al, Gynecology and cancer research, **2022**,7(6):543-547 [Crossref], [Google Scholar], [Publisher]
[44] N Esmaeilpoor et al, J Shahrood Univ Med Sci Journal, **2010**,5:1-4 [Google Scholar], [Publisher]
[45] P Roy, F Hyseni, K Mamillo et al., Radiology case Report journal, **2023**, 18(3):1364-1367 [Crossref], [Google Scholar], [Publisher]
[46] R Azhough R, Azari Y, Taher S, Jalali P. Asian Journal of Endoscopic Surgery. **2021**;14(3):458-63. [Crossref], [Google Scholar], [Publisher]
[47] R Azhough, R., Jalali, P., E J Golzari, S. et al. Indian J Surg. **2020**; **82**:824–827. [Crossref], [Google Scholar], [Publisher]
[48] R Dargahi, et al., International Journal of Women's Health and Reproduction Sciences. **2021**; 9(4):268-273. [Google Scholar], [Publisher]
[49] R Gheisari, Doroodizadeh T, Estakhri F, Tadbir A, Soufdoost R, Mosaddad S. Journal of Stomatology. **2019**;72(6):269-73. [Crossref], [Google Scholar], [Publisher]
[50] R Gheisari, Resalati F, Mahmoudi S, Golkari A, Journal of Oral and Maxillofacial Surgery. **2018**;76(8):1652.e1-.e7.[Crossref], [Google Scholar], [Publisher]
[51] R Gheisari, Resalati F, Mahmoudi S, Golkari A, Mosaddad SA. Journal of Oral and Maxillofacial Surgery. **2018**;76(8):1652.e1-.e7.[Crossref], [Google Scholar], [Publisher]
[52] R Jamali , et al., Journal of Pharmaceutical Negative Results, **2022**, 13(09) [Crossref], [Publisher]
[53] R Jamali et al, journal of pharmaceutical negative result, **2022**, 13(09): 2022 [Google Scholar], [Publisher]
[54] R Masaeli et al, Materials science and Engineering:c, **2016**, 69: 780-788 [Google Scholar], [Publisher]
[55] RA Namanloo, et al. Advances in Materials Science and Engineering. **2022** :2489399. [Crossref], [Google Scholar], [Publisher]

[56] S Cozzi, M Najafi, et al., Current Oncology, **2022** 29 (2), 881-891 [Crossref], [Google Scholar], [Publisher]
[57] S Keshmiri, SAA Mousavi Chashmi, N Abdi, E Mohammadzadeh, et al., International Journal of Early Childhood Special Education, **2022**, 14 (1), 2960-2970 [Google Scholar], [Publisher]
[58] M Akanchi et al, Journal of NeuroQuantology, **2022**, 20(8): 3015 – 3031 [Google Scholar], [Publisher]
[59] SAA Mousavi Chashmi, A comprehensive overview of the diagnosis and treatment of wounds based on the tips of various dressings and surgical methods; Book, **2023**, 1:116 [Crossref], [Google Scholar], [Publisher]
[60] SH Mashaei et al, International journal of special education, **2022**, 37(03):12655-12662, [Google Scholar], [Publisher]
[61] SH Mashaei et al, International journal of special education, **2022**, 37(03):12618-12625 [Crossref], [Google Scholar], [Publisher]
[62] S Keshmiri et al, International journal of early childhood special education, **2022**,14(01):2960-2970 [Google Scholar], [Publisher]
[63] F Hosseinzadegan et al, International journal of special education, **2022**, 37(03):12609-12617 [Crossref], [Google Scholar], [Publisher]
[64] S Zandifar et al, Journal of nephropharmacology,**2024**, 12(1) [Google Scholar], [Publisher]
[65] A Azarpey et al, Journal of parathyroid disease, **2023**, 11(1):e11238-e11238 [Google Scholar], [Publisher]
[66] A Pakmehr et al, Southern iran;journal of parasitology research, **2022,** Article ID 8406636 [Crossref], [Google Scholar], [Publisher]
[67] S EsHaghi et al, Springer,**2024**, 24(15) [Crossref], [Google Scholar], [Publisher]
[68] N Esmaeilpour et al., Journal of knowledge and health in basic medical sciences, **2013**, 1-4 [Google Scholar], [Publisher]